2 Companies, 1 Mission. Old Pharma and Prodotti Gianni together for the first time at CPHI Milano 2024, the international reference event for the pharmaceutical sector that will be held…
Eye health is a vital aspect of overall well-being that is often overlooked until visible or painful problems arise. Of the many conditions that can affect the eye, inflammation is…
In recent years, the scientific community has intensified efforts to combat antibiotic resistance. Among the new therapeutic options, in addition to Pivmecillin which we have already covered in a specific…
In recent years, the issue of drug shortages has become increasingly critical. Disruptions in the supply of essential medicines not only put patients' health at risk, but can also undermine…
In the vast arsenal of antibiotics available to modern medicine, Pivmecillin has occupied an important position since its discovery. Its use has recently sparked heated debates regarding its role in…
The health industry challenges: research, innovation and sustainability. Old Pharma awaits you from 5 to 7 June 2024 at the Rimini Palacongressi on the occasion of the 63rd AFI Symposium.…
We are proud to announce that OLD PHARMA has recently passed AIFA Med's inspection with flying colors, affirming our commitment to and compliance with Good Manufacturing Practice (GMP) standards. This…
In the intricate web of international commerce, recent events in the Middle East, notably the tumultuous situation in Yemen, have cast a spotlight on the formidable logistic challenges affecting industries…
The management of coagulation abnormalities plays a central role in many pathological conditions, especally in cardiac and vascular diseases diseases, a major cause of morbidity and mortality globally. The quest…
From 24 to 26 October 2023, the beautiful city of Barcelona will host CPHI's annual meeting for the European region. The Convention on Pharmaceutical Ingredients is a major event for…
Why has semaglutide been in the news so much lately? Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used mainly in treating type 2 diabetes, is the subject of increasing interest…